This classification divides endometrial carcinomas into four groups based on immunohistochemical (IHC) stains and molecular studies: (1) mismatch repair (MMR)-deficient: Characterized by deficient dMMR proteins; (2) p53-abnormal: Exhibits aberrant p53 expression; (3) p16-abnormal: Shows abnormal p16 expression; (4) MMR-proficient/p53-normal/p16-normal: No significant molecular alterations in these markers. This evidence concerns the gene TP53 and endometrial carcinoma.